{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:35:39Z","timestamp":1793378139706,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rmed.2026.109047","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:01:55Z","timestamp":1784530915000},"page":"109047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune checkpoint inhibitors were not associated with poor asthma control in patients with pre-existing asthma"],"prefix":"10.1016","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-8548","authenticated-orcid":false,"given":"Parker","family":"Cordial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0590-9032","authenticated-orcid":false,"given":"Sritej","family":"Devineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7561-6739","authenticated-orcid":false,"given":"Iman","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8031-2781","authenticated-orcid":false,"given":"Joanne","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-4465","authenticated-orcid":false,"given":"Kevin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2026.109047_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.rmed.2026.109047_bib2","doi-asserted-by":"crossref","first-page":"ITC17","DOI":"10.7326\/AITC202402200","article-title":"Immune-related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.109047_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.rmed.2026.109047_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2469375","article-title":"Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients","volume":"14","author":"Greib","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.rmed.2026.109047_bib5","article-title":"A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients","volume":"34","author":"Nair","year":"2021","journal-title":"Respir. Med. Case Rep."},{"issue":"9","key":"10.1016\/j.rmed.2026.109047_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.70022","article-title":"Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment","volume":"12","author":"Cordial","year":"2024","journal-title":"Respirol. Case Rep."},{"key":"10.1016\/j.rmed.2026.109047_bib7","article-title":"Eosinophilic asthma secondary to adjuvant Anti-PD-1 immune checkpoint inhibitor treatment in a melanoma patient","volume":"2022","author":"Kissoonsingh","year":"2022","journal-title":"Case Rep. Oncol. Med."},{"issue":"17","key":"10.1016\/j.rmed.2026.109047_bib8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.rmed.2026.109047_bib9","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.rmed.2026.109047_bib10","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2026.109047_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","article-title":"A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.rmed.2026.109047_bib12","article-title":"Moderate\u2010to\u2010severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.rmed.2026.109047_bib13","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1038\/s41467-020-17813-1","article-title":"PD\u20101 pathway regulates ILC2 metabolism and PD\u20101 agonist treatment ameliorates airway hyperreactivity","volume":"11","author":"Helou","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.rmed.2026.109047_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/jpm12081231","article-title":"Asthma and tobacco smoking","volume":"12","author":"Bellou","year":"2022","journal-title":"J. Personalized Med."},{"issue":"11","key":"10.1016\/j.rmed.2026.109047_bib15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.6004\/jnccn.2023.7059","article-title":"Association between pretreatment chest imaging and immune checkpoint inhibitor pneumonitis among patients with lung cancer","volume":"21","author":"Wong","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"2","key":"10.1016\/j.rmed.2026.109047_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2025.12.133","article-title":"Impact of immune checkpoint inhibitor therapy on asthma exacerbations: a nationwide retrospective cohort analysis","volume":"157","author":"Shah","year":"2026","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:44:19Z","timestamp":1793375059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126004154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":16,"alternative-id":["S0954611126004154"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109047","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors were not associated with poor asthma control in patients with pre-existing asthma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109047"}}